Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06306846
PHASE2

Neoadjuvant SBRT in Localized Advanced HNSCC

Sponsor: Jiang Feng

View on ClinicalTrials.gov

Summary

The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the prognosis of such patients. This study aims to explore the efficacy and safety of PD-1 monoclonal antibody with neoadjvant SBRT and chemotherapy. The triple mode not only can Increase the effectiveness of neoadjuvant therapy,meanwhile,the in situ tumor vaccine inoculation effect generated by enhancing the release of specific antigens after tumor radiotherapy with PD-1 monoclonal antibody achieves a sustained anti-tumor immune effect throughout the body, reducing postoperative adjuvant radiotherapy and chemotherapy. The triple mode has important exploratory value in achieving high quality and long-term survival for patients, and may provides a more efficient mode for locally advanced HNSCC.

Official title: Neoadjuvant Stereotactic Body Radiotherapy(SBRT)Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

81

Start Date

2023-10-01

Completion Date

2026-12-31

Last Updated

2024-03-12

Healthy Volunteers

No

Interventions

RADIATION

SBRT+immunochemotherpy

SBRT radiotherapy,followed with PD-1 monoclonal antibody and TP chemotherapy

DRUG

Immunochemotherapy

PD-1 monoclonal antibody and TP chemotheapy

DRUG

cetuximab+immunochemotharpy

PD-1 monoclonal antibody and TP chemotheapy combined with cetuximab

Locations (1)

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China